Combination with an antisense oligonucleotide synergistically improves the antileukemic efficacy of erucylphospho-N,N,N-trimethylpropylammonium in chronic myeloid leukemia cell lines

Molecular Cancer Therapeutics

Volumn 1, Issue 10, 2002, Pages 877-884

  Konstantinov, Spiro M ^c,d   Georgieva, Milka C ^c,e   Topashka Ancheva, Margarita ^a   Eibl, Hansjörg ^b   Berger, Martin R ^c  

^a INSTITUTE OF BIODIVERSITY AND ECOSYSTEM RESEARCH   (Bulgaria)

^b MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^e National Oncology Center Bulgaria   (Bulgaria)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BCR ABL PROTEIN; ERUCYLPHOSPHO N,N,N TRIMETHYLPROPYLAMMONIUM; ERUCYLPHOSPHO-N,N,N-TRIMETHYLPROPYLAMMONIUM; ORGANOPHOSPHATE; QUATERNARY AMMONIUM DERIVATIVE;

ANIMAL; ARTICLE; BIOSYNTHESIS; C57BL MOUSE; CELL CULTURE; CELL DIVISION; CELL STRAIN HL 60; CELL STRAIN K 562; CHRONIC MYELOID LEUKEMIA; FEMALE; GENETIC TRANSFECTION; HUMAN; MOUSE; TIME; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL DIVISION; FEMALE; FUSION PROTEINS, BCR-ABL; HL-60 CELLS; HUMANS; K562 CELLS; LEUKEMIA, MYELOID, CHRONIC; MICE; MICE, INBRED C57BL; OLIGONUCLEOTIDES, ANTISENSE; PHOSPHORIC ACID ESTERS; QUATERNARY AMMONIUM COMPOUNDS; TIME FACTORS; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0036690594     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Verfaillie, C. M. Biology of chronic myeloid leukemia. Hematol./Oncol. Clin. North Am., 12: 1-29, 1998.
2. Carlesso, N., Frank, D. A., and Griffin, J. D. Use of temperature sensitive mutant to define biological effects of the p210 BCR-ABL tyrosine kinase on proliferation of a factor dependent murine cell line. Oncogene, 9: 149-156, 1994.
3. Daley, G. Q., and Baltimore, D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc. Natl. Acad. Sci. USA, 85: 9312-9316, 1988. (Pubitemid 19001887)
4. Kantarjian, H. M., Giles, F. J., O'Brien, S. M., and Talpaz, M. Clinical course and therapy of chronic myelogenous leukemia with interferon-α and chemotherapy. Hematol./Oncol. Clin. North Am., 12: 31-79, 1998.
5. Brunstein, C. G., and McGlave, P. B. The biology and treatment of chronic myelogenous leukemia. Oncology, 15: 23-31, 2001.
6. Druker, B. J., Sawyers, C. L, Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., and Talpaz, M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med., 344: 1038-1042, 2001. (Pubitemid 32267973)
7. Gewirtz, A. M. Oligonucleotide therapeutics: clothing the emperor. Curr. Opin. Mol. Ther., 1: 297-306, 1999. (Pubitemid 29309177)
8. Berger, M. R., Yanapirut, P., Reinhardt, M., Klenner, T., Scherf, H. R., Schmeiser, H. H., and Eibl, H. Antitumor activity of alkylphosphocholines and analogues in methylnitrosourea-induced rat mammary carcinoma. In: H. Eibl, P. Hilgard, and C. Unger (eds.), New Drugs in Cancer Therapy, Progress in Experimental Tumor Research 34, pp. 98-115. Basel: Karger, 1992.
9. Berger, M. R., Betsch, B., Gebelein, M., Amtmann, E., Heyl, P., and Scherf, H. R. Hexadecylphosphocholine differs from conventional cytostatic agents. J. Cancer Res. Clin. Oncol., 119: 541-548, 1993. (Pubitemid 23180045)
10. Eibl, H., and Unger, C., Hexadecylphosphocholine: a new and selective antitumor drug. Cancer Treat. Rev., 17: 233-242, 1992.
11. Konstantinov, S. M., Topashka-Ancheva, M., Benner, A., and Berger, M. R. Alkylphosphocholines: effects on human leukemic cell lines and normal bone marrow cells. Int. J. Cancer, 77: 778-786, 1998. (Pubitemid 28341397)
12. Berger, M. R., Sobottka, S., Konstantinov, S. M., and Eibl, H. Erucylphosphocholine is the prototype of i.v. injectable alkylphosphocholines. Drugs Today, 34 (Suppl. F): 73-81, 1998. (Pubitemid 29046798)
13. Hilgard, P., Klenner, T., and Engel, J. Inhibitors of the signal transduction: the alkylphosphocholines. Drug News Perspect., 12: 69-72, 1999.
14. Konstantinov, S. M., Eibl, H., and Berger, M. R. BCR-ABL influences the antileukemic efficacy of alkylphosphocholines. Br. J. Haematol., 107: 365-374, 1999. (Pubitemid 29530225)
15. Drexler, H. G., Roderick, A. F. McLeod, C., and Uphoff, C. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia. Leuk. Res., 23: 207-215, 1999. (Pubitemid 29083376)
16. Eibl, H., and Engel, J. Synthesis of hexadecylphosphocholine (Miltefosine). In: H. Eibl, P. Hilgard, and C. Unger (eds.), New Drugs in Cancer Therapy, Progress in Experimental Tumor Research 34, pp. 1-5. Basel: Karger, 1992.
17. McGahon, A. J., Bissonette, R. P., Schmitt, M., Cotter, K., Green, D. R., and Cotter, T. G. Bcr-Abl maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood, 83: 1179-1187, 1994. (Pubitemid 24062839)
18. Dunn, O. J. Multiple comparison using rank sums. Technometrics, 6: 241-252, 1964.
19. Stuart, A., Ord, J. K., and Arnold, I. (eds.). Kendall's Advanced Theory of Statistics 2A, ed. 6, pp. 538-734. London: Arnold, 1999.
20. Berenbaum, M. C. What is synergy?. Pharmacol. Rev., 41: 93-141, 1989. (Pubitemid 20019599)
21. Chou, T. C., and Talalay, P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul., 22: 27-55, 1984.
22. Diomede, L., Colotta, F., Piovani, B., Re, F., Modest, E. J., and Salmona, M. Induction of apoptosis in human leukemic cells by the ether lipid 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine. A possible basis for its selective action. Int. J. Cancer, 53: 124-130, 1993. (Pubitemid 23018434)
23. Diomede, L., Piovani, B., Re, F., Principe, P., Colotta, F., and Modest, E. J. The induction of apoptosis is a common feature of the cytotoxic action of ether-linked glycerophospholipids in human leukemic cells. Int. J. Cancer, 57: 645-649, 1994. (Pubitemid 24201353)
24. Wada, H., Mizutani, S., Nishimura J., Usuki, Y., Kohsaki, M., Komai, M., Kaneko, H., Sakamoto, S., Delia, D., and Kanamuru, A. Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR/ABL fusion protein. Cancer Res., 55: 3192-3196, 1995.
25. Le Coutre, P., Tassi, E., Varella-Garcia, M., Barni, R., Mologni, L., Cabrita, G., Marchesi, E., Supino, R., and Gambacorti-Passerini, C. Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood, 95: 1758-1766, 2000. (Pubitemid 30120840)
26. Issaad, C., Ahmed, M., Novoult, S., Bonnet, M. L., Bennardo, T., Varet, B., Vainchenker, W., and Turhan, A. G. Biological effects induced by variable levels of BCR-ABL protein in the pluripotent hematopoietic cell line UT-7. Leukemia (Baltimore), 14: 662-670, 2000. (Pubitemid 30195457)
27. Amarante-Mendez, G., Kim, C. N., Liu, L., Huang, Y., Perkins, C., Green, D., and Bhalla, K. BCR-ABL exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3. Blood, 91: 1700-1705, 1998. (Pubitemid 28110335)
28. Skorski, T., Nieborowska-Skorska, M., Wlodarski, P., Perroti, D., Hoser, G., Kawiak, J., Majewski, L., Christensen, L., Iozzo, R. V., and Calabretta, B. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligonucleotides. J. Natl. Cancer Institute, 89: 124-133, 1997. (Pubitemid 27034788)
29. Liu, Y., and Bergan, R. Improved intracellular delivery of oligonucleotides by square wave electroporation. Antisense Nucleic Acid Drug Dev., 11: 7-14, 2001. (Pubitemid 32199391)
30. Van Tendeloo, V. F. I., Ponsaerts, P., Lardon, F., Nijs, G., Lenjou, M., Van Broeckhoven, C., Van Bockstaele, D. R., and Berneman, Z. N. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading dendritic cells. Blood, 98: 49-56, 2001.
31. Baker, E. A., Vaughn, M. W., and Haviland, D. L. Choices in transfection methodologies: transfection efficacy should not be the sole criterion. Focus, 22: 31-33, 2000.
32. Sawyers, L. C. Research on resistance to cancer drug Gleevec. Science (Wash. DC), 294: 1834, 2001.
33. Barthe, C., Cony-Makhoul, P., Melo, J. V., Reiffers, J., and Mahon, F. X. Roots of clinical resistance to STI-571 cancer therapy. Science (Wash. DC), 293 (5538): 2163, 2001.
34. Hochhaus, A., Kreil, S., Corbin, A., La Rosee, P., Lahaye, T., Berger, U., Cross, N., Linkesch, W., Druker, B. J., and Hehlmann, R. Roots of clinical resistance to STI-571 cancer therapy. Science (Wash. DC), 293: 2163, 2001.